Zhong Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhong Lu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Baishuang Yue
A Department of Dermatology, Huashan Hospital , Fudan University , Shanghai , China
2 shared publicationsHuihui Gan
A Department of Dermatology, Huashan Hospital , Fudan University , Shanghai , China
1 shared publicationJinhua Xu
Department of Dermatology, Huashan Hospital, Fudan University, No. 12 Wulumuqi Road, Jing'an District, Shanghai, 200040, China
1 shared publicationQianli Yang
Department of Dermatology, Huashan Hospital, Fudan University, No. 12 Wulumuqi Road, Jing'an District, Shanghai, 200040, China
1 shared publicationYan Wang
A Department of Dermatology, Huashan Hospital , Fudan University , Shanghai , China
1 shared publication
Latest Publications
- 20 February 2018
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 20 (7-8) , 442-446
Treatment of facial telangiectasia with narrow-band intense pulsed light in Chinese patients
Objective: To evaluate the efficacy and safety of narrow-band intense pulsed light (DPL) in treating facial telangiectasia. Method: Thirty patients with facial telangiectasia underwent five sessions of treatment with DPL (500 nm~600 nm) at 4-week interval. The erythema index (EI), temperature, transepidermal water loss (TEWL), and lightness of the skin (L) were measured before each treatment session and at each follow-up. Result: Thirty cases completed treatment and follow-ups. Twenty-seven cases (90%) got more than 50% clearance post-treatment and among them eight cases (27%) got more than 75% clearance. The average of the mean EI value decreased with the number of treatment sessions; the EI observed after two treatment sessions was significantly different from that observed before treatment (P = 0.012, P < 0.05). The decrease in skin temperature and TEWL values post-treatment was statistically significant (P = 0.000, P = 0.027, P < 0.05), while the L value increased significantly (P = 0.025, P < 0.05). Thirty percent cases had reccurence at 6-month follow-up. While burning sensation, erythema, and swelling were usually seen during the treatment, no severe side effects were observed during treatment and follow-ups. Conclusion: Narrow-band intense pulsed light DPL is effective and safe in treating facial telangiectasia.
- 20 February 2018
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 20 (7-8) , 442-446
Treatment of facial telangiectasia with narrow-band intense pulsed light in Chinese patients
Objective: To evaluate the efficacy and safety of narrow-band intense pulsed light (DPL) in treating facial telangiectasia. Method: Thirty patients with facial telangiectasia underwent five sessions of treatment with DPL (500 nm~600 nm) at 4-week interval. The erythema index (EI), temperature, transepidermal water loss (TEWL), and lightness of the skin (L) were measured before each treatment session and at each follow-up. Result: Thirty cases completed treatment and follow-ups. Twenty-seven cases (90%) got more than 50% clearance post-treatment and among them eight cases (27%) got more than 75% clearance. The average of the mean EI value decreased with the number of treatment sessions; the EI observed after two treatment sessions was significantly different from that observed before treatment (P = 0.012, P < 0.05). The decrease in skin temperature and TEWL values post-treatment was statistically significant (P = 0.000, P = 0.027, P < 0.05), while the L value increased significantly (P = 0.025, P < 0.05). Thirty percent cases had reccurence at 6-month follow-up. While burning sensation, erythema, and swelling were usually seen during the treatment, no severe side effects were observed during treatment and follow-ups. Conclusion: Narrow-band intense pulsed light DPL is effective and safe in treating facial telangiectasia.
- 23 July 2016
- Published by Springer Nature in Lasers in Medical Science
- Vol. 31 (8) , 1657-1663
Efficacy and safety of fractional Q-switched 1064-nm neodymium-doped yttrium aluminum garnet laser in the treatment of melasma in Chinese patients
Melasma is an acquired disorder of symmetrical hyperpigmentation commonly seen in patients with Fitzpatrick skin types III and IV. Various novel therapeutic modalities have emerged to treat melasma. The large-spot low-fluence QS Nd:YAG laser has been widely used in Asia; however, the modality needs to be optimized because of the high recurrence rate. The objective of this study is to explore the clinical efficacy and safety of fractional-mode (Pixel) Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm laser for treatment of melasma in Chinese patients. Twenty-seven patients were enrolled and completed all the treatment sessions and the 12-week follow-up. All were treated using the fractional-mode Pixel QS Nd:YAG (1064 nm) laser for eight sessions at a 2–3-week interval. Clinical photographs were taken using the Visia skin analysis imaging system. Two blinded assessors evaluated melasma area and severity index (MASI) scores before and 4 weeks after the final session. Melanin index (MI) and erythema index (EI) was measured before each treatment visit and after the final treatment. The degree of pigmentation and erythema was assessed using a tristimulus color analyzer. Physicians’ global assessment (PGA) and patients’ self-assessment were taken as the subjective assessments. Wilcoxon signed-rank test was performed to evaluate clinical response. Recurrence rate were also evaluated. Mean MASI scores decreased from 12.84 ± 6.89 to 7.29 ± 4.15 after treatment (p = 0.000). Seventy percent of patients got moderate to good improvements after all the treatment. Mean MI decreased significantly from 56.52 ± 23.35 to 32.75 ± 12.91 (p = 0.000). L value increased from 59.21 ± 2.22 before treatment to 61.60 ± 2.40 (p = 0.000) after therapy. The mean score of PGA was 3.76 ± 0.71, indicating a “moderate” clearance of the lesion. In patients’ self-evaluations, 70 % of the patients rated the result as “good” to “remarkable.” Partial recurrence was seen in 40 % patients at the 3-month follow-up. No severe adverse events were observed during the study, and the treatment was well tolerated. The fractional mode (Pixel) QS Nd:YAG 1064-nm laser is an effective and safe treatment for melasma. The recurrence rate was relatively lower than that reported in studies treating with large-spot low-fluence QS Nd:YAG laser.
- 23 July 2016
- Published by Springer Nature in Lasers in Medical Science
- Vol. 31 (8) , 1657-1663
Efficacy and safety of fractional Q-switched 1064-nm neodymium-doped yttrium aluminum garnet laser in the treatment of melasma in Chinese patients
Melasma is an acquired disorder of symmetrical hyperpigmentation commonly seen in patients with Fitzpatrick skin types III and IV. Various novel therapeutic modalities have emerged to treat melasma. The large-spot low-fluence QS Nd:YAG laser has been widely used in Asia; however, the modality needs to be optimized because of the high recurrence rate. The objective of this study is to explore the clinical efficacy and safety of fractional-mode (Pixel) Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm laser for treatment of melasma in Chinese patients. Twenty-seven patients were enrolled and completed all the treatment sessions and the 12-week follow-up. All were treated using the fractional-mode Pixel QS Nd:YAG (1064 nm) laser for eight sessions at a 2–3-week interval. Clinical photographs were taken using the Visia skin analysis imaging system. Two blinded assessors evaluated melasma area and severity index (MASI) scores before and 4 weeks after the final session. Melanin index (MI) and erythema index (EI) was measured before each treatment visit and after the final treatment. The degree of pigmentation and erythema was assessed using a tristimulus color analyzer. Physicians’ global assessment (PGA) and patients’ self-assessment were taken as the subjective assessments. Wilcoxon signed-rank test was performed to evaluate clinical response. Recurrence rate were also evaluated. Mean MASI scores decreased from 12.84 ± 6.89 to 7.29 ± 4.15 after treatment (p = 0.000). Seventy percent of patients got moderate to good improvements after all the treatment. Mean MI decreased significantly from 56.52 ± 23.35 to 32.75 ± 12.91 (p = 0.000). L value increased from 59.21 ± 2.22 before treatment to 61.60 ± 2.40 (p = 0.000) after therapy. The mean score of PGA was 3.76 ± 0.71, indicating a “moderate” clearance of the lesion. In patients’ self-evaluations, 70 % of the patients rated the result as “good” to “remarkable.” Partial recurrence was seen in 40 % patients at the 3-month follow-up. No severe adverse events were observed during the study, and the treatment was well tolerated. The fractional mode (Pixel) QS Nd:YAG 1064-nm laser is an effective and safe treatment for melasma. The recurrence rate was relatively lower than that reported in studies treating with large-spot low-fluence QS Nd:YAG laser.